A detailed history of Krane Funds Advisors LLC transactions in Amgen Inc stock. As of the latest transaction made, Krane Funds Advisors LLC holds 927 shares of AMGN stock, worth $259,569. This represents 0.01% of its overall portfolio holdings.

Number of Shares
927
Previous 299 210.03%
Holding current value
$259,569
Previous $96,000 210.42%
% of portfolio
0.01%
Previous 0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$309.38 - $337.38 $194,290 - $211,874
628 Added 210.03%
927 $298,000
Q3 2024

Oct 16, 2024

BUY
$309.38 - $337.38 $92,504 - $100,876
299 New
299 $96,000
Q3 2023

Nov 13, 2023

SELL
$218.65 - $271.46 $58,160 - $72,208
-266 Reduced 10.34%
2,307 $620,000
Q2 2023

Aug 11, 2023

BUY
$214.27 - $253.37 $31,283 - $36,992
146 Added 6.02%
2,573 $571,000
Q1 2023

May 12, 2023

BUY
$225.79 - $275.2 $18,514 - $22,566
82 Added 3.5%
2,427 $610,000
Q4 2022

Feb 10, 2023

SELL
$229.03 - $291.01 $120,011 - $152,489
-524 Reduced 18.26%
2,345 $616,000
Q3 2022

Nov 14, 2022

SELL
$224.46 - $253.15 $76,540 - $86,324
-341 Reduced 10.62%
2,869 $647,000
Q2 2022

Aug 11, 2022

BUY
$230.71 - $256.74 $343,065 - $381,772
1,487 Added 86.3%
3,210 $781,000
Q1 2022

May 11, 2022

BUY
$219.27 - $242.57 $16,445 - $18,192
75 Added 4.55%
1,723 $417,000
Q4 2021

Feb 10, 2022

SELL
$198.88 - $227.6 $33,212 - $38,009
-167 Reduced 9.2%
1,648 $371,000
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $17,830 - $20,890
-84 Reduced 4.42%
1,815 $386,000
Q2 2021

Aug 12, 2021

BUY
$233.58 - $259.14 $443,568 - $492,106
1,899 New
1,899 $463,000
Q1 2021

May 14, 2021

SELL
$221.91 - $258.6 $109,401 - $127,489
-493 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$216.38 - $257.67 $106,675 - $127,031
493 New
493 $113,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $150B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Krane Funds Advisors LLC Portfolio

Follow Krane Funds Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Krane Funds Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krane Funds Advisors LLC with notifications on news.